Association Between Vitamin D and Resistin in Postmenopausal Females With Altered Bone Health
Overview
Affiliations
Background: Resistin is a relatively novel adipokine that has a role in bone remodeling and may regulate bone mineral density (BMD). Vitamin D and adipokines have a dynamic role in the body's various metabolic processes, including bone metabolism, and may alter bone metabolism in relation to each other. This study aimed to investigate the association between vitamin D and serum resistin levels in postmenopausal non-osteoporotic and osteoporotic females.
Methods: This correlational analytical study was conducted on 161 postmenopausal females, divided into two groups, non-osteoporotic and osteoporotic, between 50-70 years. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA) scan. Serum resistin and vitamin D levels were analyzed by enzyme-linked immunosorbent assay (ELISA) method. Serum calcium, phosphate, and alkaline phosphatase with spectrophotometry. A correlation was checked using spearman's rho correlation coefficient, and multivariate stepwise regression analysis was used to predict serum resistin levels.
Results: Postmenopausal females (n=161) having sufficient, insufficient and deficient levels of vitamin D were 87 (54.0%), 64 (39.8%), and 10 (6.2%), respectively. Lumbar spine BMD (p < 0.001), total hip BMD (p < 0.001), and serum resistin levels (p < 0.001) were significantly different between the two groups. There was a significant negative correlation between serum resistin and vitamin D in postmenopausal females (rho = -0.182, p = 0.021) and osteoporotic group (rho = -0.253, p = 0.019) but non-significant in non-osteoporotic group (rho = -0.077, p = 0.509). Serum vitamin D was found to be independent predictor of serum resistin levels, accounting for only 3% variance.
Conclusion: Serum vitamin D levels were low while serum resistin levels were high in postmenopausal osteoporotic females and vitamin D is a negative predictor of serum resistin levels.
Karampatsou S, Paltoglou G, Genitsaridi S, Kassari P, Charmandari E Nutrients. 2024; 16(21).
PMID: 39519480 PMC: 11547676. DOI: 10.3390/nu16213646.
Diaz P, Cadena M, Montalvan M, Garrochamba K, Calderon P, Carrion G Front Nutr. 2024; 11:1482910.
PMID: 39391680 PMC: 11464991. DOI: 10.3389/fnut.2024.1482910.
Geryk M, Kucerova V, Velganova-Veghova M, Foltenova H, Bouchalova K, Karasek D BMC Pediatr. 2024; 24(1):426.
PMID: 38961351 PMC: 11223338. DOI: 10.1186/s12887-024-04890-0.
Editorial: Osteoporosis and adipokines: the potential for future treatment.
Tariq S, Tariq S, Baig M, Valjevac A Front Endocrinol (Lausanne). 2024; 15:1405412.
PMID: 38660520 PMC: 11039904. DOI: 10.3389/fendo.2024.1405412.
The role of adipokines in osteoporosis management: a mini review.
Patil J, Fredericks S Front Endocrinol (Lausanne). 2024; 15:1336543.
PMID: 38516409 PMC: 10956128. DOI: 10.3389/fendo.2024.1336543.